Cervical cancers exhibited genomic alterations in either one or both of the PI3K-MAPK and TGFβ pathways, illustrating the potential clinical significance of therapeutic agents targeting members of these pathways [8,9,10] (Figure 1). The gene discussed is PIK3CA; the disease is cervical cancer.